Metabolic syndrome (MS) is one of the leading risk factors for the development of some common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer). Currently, a drug-induced metabolic syndrome related with androgen deprivation therapy in patients with prostate cancer represents a serious medical problem. Not only MS, or its individual components, but MS variants with different levels of leptin, adiponectin, visfatin, resistin are associated with tumor invasion, metastasis and survival rates in patients with MS-associated malignancies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dsx.2018.04.028 | DOI Listing |
Publication Analysis
Top Keywords
metabolic syndrome
12
role metabolic
4
syndrome variant
4
variant malignant
4
malignant tumors
4
tumors progression
4
progression metabolic
4
syndrome leading
4
leading risk
4
risk factors
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!